Posted by Michael Wonder on 20 Mar 2023
Arrowhead receives FDA fast track designation for ARO-APOC3
20 March 2023 - Arrowhead Pharmaceuticals today announced the US FDA has granted fast track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronaemia syndrome.
ARO-APOC3 is Arrowhead’s investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3) being developed as a treatment for patients with severe hypertriglyceridaemia, mixed dyslipidaemia and familial chylomicronaemia syndrome.
